5-HT1A receptor
8 drugs CNS
4
approved indications
8
Approved Drugs
7
Companies
7
Indications
1
Therapeutic Areas
Top Drugs
Unlock Full Target Intelligence PRO
✓ Competitive landscape by company (7 companies)
✓ All 8 approved drugs
✓ Therapeutic area breakdown
✓ Full indication list (7 indications)
✓ Patent cliff analysis
✓ Clinical trials pipeline
Upgrade to Pro
Starting at $99/mo
Drugs by Company
ALKERMES INC 2 drugs
XIAMEN LP PHARM CO 1 drug
UNICHEM 1 drug
By Therapeutic Area
CNS 8 drugs
Drugs by Company PRO
ALKERMES INC 2 drugs
XIAMEN LP PHARM CO 1 drug
UNICHEM 1 drug
OTSUKA PHARM CO LTD 1 drug
AbbVie 1 drug
OTSUKA 1 drug
Takeda 1 drug
By Therapeutic Area
CNS 8 drugs
OPIPZA, ARIPIPRAZOLE, ABILIFY MAINTENA KIT, VRAYLAR +4 more
Indications Treated
SchizophreniaAutistic DisorderTourette’s DisorderMajor Depressive DisorderAutismTourette SyndromeBipolar I Disorder
All Drugs Targeting 5-HT1A receptor
| Drug | Company | Approved | Indications | Therapeutic Area |
|---|---|---|---|---|
| OPIPZA | XIAMEN LP PHARM CO | 2024 | 4 | CNS |
| ARIPIPRAZOLE | UNICHEM | 2015 | 3 | CNS |
| ABILIFY MAINTENA KIT | OTSUKA PHARM CO LTD | 2013 | 3 | CNS |
| VRAYLAR | AbbVie | 2015 | 2 | CNS |
| ABILIFY ASIMTUFII | OTSUKA | 2023 | 2 | CNS |
| ARISTADA INITIO KIT | ALKERMES INC | 2018 | 1 | CNS |
| TRINTELLIX | Takeda | 2013 | 1 | CNS |
| ARISTADA | ALKERMES INC | 2015 | 1 | CNS |